Zenas BioPharma Prices $300 Million Offering; Stock Down

Zenas BioPharma priced concurrent offerings totalling $300.0M: $200.0M of convertible senior notes due 2032 and $100.0M of common stock, providing near-term liquidity for the clinical-stage autoimmune biotech. The transaction should reduce near-term financing risk but will dilute equity and add long-term convertible debt on the balance sheet.

Analysis

Zenas BioPharma priced concurrent offerings totalling $300.0M: $200.0M of convertible senior notes due 2032 and $100.0M of common stock, providing near-term liquidity for the clinical-stage autoimmune biotech. The transaction should reduce near-term financing risk but will dilute equity and add long-term convertible debt on the balance sheet.